Actively Recruiting

Age: 1Month - 120Years
All Genders
NCT07019155

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Led by National Cancer Institute (NCI) · Updated on 2026-04-30

510

Participants Needed

1

Research Sites

516 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and these diseases. Objective: To study the link between HHM and MDS/AML. Eligibility: People aged 1 month and older with HHM. Relatives with HHM are also needed. Design: Participants aged 3 years and older will have 1 initial clinic visit with the option to follow-up annually. They will undergo these procedures: They will have a physical exam with blood and urine tests. They may give samples of saliva, stool, nails, and skin. Their ability to do normal activities will be reviewed. Some may have a bone marrow biopsy: A tissue sample will be drawn from inside a bone. They may answer questions about their health and family medical history. Participants younger than 3 years, and those who cannot come to the clinic, will be contacted by phone or email. Their samples may be collected locally and sent to researchers. For participants who have changes in their DDX41 gene: Researchers will contact them or their primary care provider once a year for 10 years. Researchers will check on participants health and collect any new test results. Some may be asked to send new samples. Participants who do not have changes in their DDX41 gene may be contacted yearly, or less often, for 10 years. Some participants may be asked to return to the clinic if needed.

CONDITIONS

Official Title

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Who Can Participate

Age: 1Month - 120Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age greater than 1 month old
  • Participants with confirmed aberrations affecting the DDX41 gene, DDX41 RNA, or DDX41 protein
  • Participants with confirmed aberrations in another hereditary hematopoietic malignancy (HHM) variant
  • Participants without HHM variants who have a first or second degree relative with confirmed or suspected HHM variants
  • Participants must have a healthcare provider outside NIH managing their care and diagnostic findings
  • Ability to understand and willingness to sign a written consent document
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

R

Rebecca B Alexander

CONTACT

S

Sung-Yun Pai, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here